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The First Successful Transapical Aortic Valve Implant in Korea
Transcatheter aortic valve implantation is an alternative to open heart surgery in high risk 
patients with severe aortic stenosis. High mortality and complications related to 
cardiopulmonary bypass for conventional open heart surgery can be avoided with this new 
less invasive technique. In case of concomitant severe arterial disease, the transapical 
approach is recommended rather than transfemoral access. An 80-yr-old man with 
symptomatic aortic stenosis and who had very high surgical risk factors such as diabetes 
mellitus, hypertension, a history of stroke, bronchial asthma including poor pulmonary 
function and hepatocellular carcinoma was treated with a transapical aortic valve 
replacement. The expected mortality in this patient was 25.4% by Euroscore if we 
performed the conventional aortic valve surgery. The patient was discharged and was well 
at the 45 follow-up days. We report the first case of successful transcatheter transapical 
aortic valve implantation which is available recently in Korea. 
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CASE REPORT
Cardiovascular Disorders
INTRODUCTION
Surgical aortic valve replacement (AVR) remains the gold stan-
dard therapy for patients with symptomatic severe aortic steno-
sis (1). But for elderly patients with symptomatic severe aortic 
stenosis and who have significant comorbidities, conventional 
open heart AVR with cardiopulmonary bypass can be related 
with an unacceptable high morbidity and mortality. One of the 
alternative techniques using endoscope was introduced as less 
invasive valve surgery but were not popular in terms of cost and 
safety (2). Over the past 5 yr, transcatheter aortic valve implan-
tation (TAVI) has been performed worldwide (3-5). However, in 
terms of transarterial access, limitations remain due to the de-
livery sheath profiles, and especially in patients with small, dis-
eased or tortuous access vessels. In these cases, transapical TAVI 
can be preferred. Ye et al. reported the first successful off pump 
transapical TAVI through a left minithoracotomy and the apex 
of the left ventricle (1). We describe performing the first success-
ful transapical TAVI for a very high risk patient in Korea.
CASE DESCRIPTION
An 80-yr-old Korean man with severe degenerative aortic ste-
nosis visited our hospital for chest tightness and dyspnea on ex-
ertion (NYHA functional class III). He had a past medical histo-
ry of diabetes mellitus and hypertension, a history of stroke at 
the right pontine 3 yr ago, bronchial asthma for over 40 yr, chron-
ic obstructive pulmonary disease with severe emphysematous 
changes and hepatocellular carcinoma that was treated with 
three sessions of transarterial embolization in June 2008. The 
logistic EuroScore was 25.3% (Age, chronic pulmonary disease, 
neurologic dysfunction, and critical preoperative state) and the 
Society of Thoracic Surgeons (STS) score was 10.4%. The com-
puterized tomographic angiogram showed extensive ascending 
aorta and arch calcification. The patient was recommended to 
undergo transcatheter aortic valve implantation due to his co-
morbidities. We chose the transapical TAVI because his iliofem-
oral vessels were diseased and too small for transfemoral access 
(diameter of left femoral artery, 8.3 mm and diameter of right 
femoral artery, 7.8 mm).
  On echocardiography, the aortic valve area was 0.9 cm
2, the 
maximal velocity was 4.1 m/s and the mean pressure gradient 
was 35 mmHg. The aortic valve consisted of three cusps and the 
diameter of the annulus was 20.2 mm. The left ventricular ejec-
tion fraction was 65%. The coronary arteries were normal ac-
cording to coronary angiography. 
  Informed consent was obtained from the patient and his fam-
ily. The TAVI was performed in the hybrid room where open 
heart surgeries and interventions were possible. All the proce-
dures were prechecked by anesthesiologist, cardiologists and Jeong DS, et al.  •  Transapical Aortic Valve Implant
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cardiac surgeons.
  General anesthesia for open heart surgery was performed 
along with transesophageal echocardiography (TEE), placing a 
Swan-Ganz catheter and continuous arterial pressure monitor-
ing at a radial artery. Right inguinal venous and arterial access 
was obtained for placing the pacing wire in the right ventricle 
and a pigtail catheter in the aortic root. 
  After a left anterior mini-thoracotomy, the pericardium was 
opened. The left ventricular apex was prepared for puncture with 
two pledgeted purse-string sutures. Heparin was administered 
to achieve an activated clotting time of 300 sec or more with an 
initial dose of 150 μ/kg. After heparinization, a 7 F Angiocath 
was inserted through the apex of the left ventricle and a guide-
wire was passed through the aortic valve. This guide wire was 
exchanged for a 0.035-inch Amplatz Extra Stiff guide wire, which 
was placed across the aortic arch and the tip was positioned in 
the abdominal aorta for stability. The Angiocath was also ex-
changed for a 14 F catheter, and then 20 mm balloon valvulo-
plasty was performed. During the balloon valvuloplasty, rapid 
ventricular pacing of 200 beats/min was used to reduce the trans-
aortic flow (Fig. 1A). A 26 F introducer sheath was subsequently 
introduced into the apex, and a 26 mm Sapien transcatheter 
heart valve (THV) (Edward Lifesciences, Irvine, CA, USA) was 
deployed under pacing of 200 beats/min. The position of the 
THV was checked with a root aortogram using a pig tail cathe-
ter before and after deployment. After full deployment of the 
THV, the root aortogram and coronary angiography revealed 
the optimal position of the bioprosthesis and normal coronary 
perfusion (Fig. 1B). The immediate post-deployment transesoph-
ageal echocardiography showed a good position, normal leaflet 
motion, no paravalvular leakage and a mean pressure gradient 
of 9.6 mmHg. Anesthesia was reversed, but extubation was put 
off due to the poor preoperative pulmonary function. The pa-
tient was discharged without problems on the 17th postopera-
tive day after the management of asthma. The postoperative 
echocardiographic findings showed good prosthetic valve func-
tion and good left ventricular ejection fraction. The patient was 
well at the 45 follow-up days and he had had an improved func-
tional status of NYHA class I.
DISCUSSION
This case is the first successful transapical TAVI in Korea. Recent-
ly, the clinical results of AVR are improving in elderly patients. 
The early mortality for septuagenarians and octogenarians who 
are undergoing isolated AVR ranges from 4.0% to 16.7% (6-8). 
However, the real risk of conventional AVR remains unclear in 
elderly high-risk patients. According to some previous reports 
of TAVI, the predicted operative mortality for conventional AVR 
was above 30% according to the logistic EuroScore (9).
  The transapical TAVI is a viable alternative for high risk patients 
with severe aortic stenosis and who are not suitable for open 
heart surgery. The representative indications may be patients of 
aortic stenosis with severe ascending aortic calcification, previ-
ous multiple coronary artery bypass surgery with patent grafts 
crossing sternum, or valve-in-valve implantation for degenera-
tive bioprosthesis. Ye et al. (9) showed their improvement of 30-
day mortality of transapical TAVI from 33.3% to 12.5% in 15 pa-
A B
Fig. 1. Aortogram showing transcatheter transapical aortic valve implant. (A) Rapid pacing of 200 beats/min was performed to reduce the transaortic flow during the deployment 
of prosthetic aortic valve. (B) Both coronary arteries were clearly visible after aortic valve implant.Jeong DS, et al.  •  Transapical Aortic Valve Implant
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tients through the learning curve. They emphasized teamwork, 
meticulous apical hemostasis, the use of a well-equipped hy-
brid operating room, understanding the risk factors for poten-
tial fatal events and aggressive postoperative care. The predict-
ed mortality in our patient was 25.3% by the logistic EuroScore 
and 10.4% by the STS score, which is considered a high risk. This 
is similar to the first Asian TAVI reported in Singapore (10). Among 
several risk factors, the poor pulmonary function caused by 
chronic obstructive pulmonary disease with severe emphyse-
matous changes was the most important obstacle against per-
forming conventional open heart surgery. Only brief anesthesia 
enabled the patient to recover without any pulmonary compli-
cations, which could be easily predicted following conventional 
AVR and using cardiopulmonary bypass. 
  As for the team approach and equipment, we prepared for a 
long time to successfully perform transapical TAVI. The hybrid 
operating room that included a primed cardiopulmonary by-
pass system and a full open heart surgery set were arranged. 
The team consisted of one cardiac anesthesiologist, three cardi-
ologists, one vascular surgeon and two dexterous interventional 
radiology technicians. All the team completely understood the 
procedure and everyone concentrated on their roles during all 
the process. Rehearsal for the first TAVI was performed several 
times.
  There are two representative devices for TAVI. One is the Sapi-
en THV and the other is CoreValve. The CoreValve system has 
an advantage over Sapien THV as it is fully retrievable as long as 
the introducer catheter is not released from the valve. There 
were several reports that showed good early results with using 
the CoreValve (11). However, the incidence of having to place a 
permanent pacemaker was increased with using the CoreValve 
(12). Godin et al. (13) recently reported that the Sapien THV re-
vealed a low incidence of heart block. We believed these reports 
and we chose the Sapien THV in hope of avoiding the require-
ment of implanting a permanent pacemaker. Our patient had 
normal sinus rhythm at the last follow up.
  In summary, the transapical TAVI which is available in our 
country recently could be performed safely and it showed a good 
clinical outcome. Complete equipment, a team approach, and 
preparation for unwanted fatal complications were required to 
achieve a successful result.
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